Search results
Results from the WOW.Com Content Network
Injection of drugs in the last six months with sharing of equipment Serodiscordant heterosexual and homosexual partners, where one partner is HIV-positive and the other HIV-negative The consideration of utilizing emtricitabine/tenofovir as a reduction strategy involves discussion with a health professional who can help the patient navigate the ...
(Reuters) -Gilead Sciences said on Thursday a late-stage study showed its long-acting injectable drug was more effective in preventing HIV infection in women compared to its existing daily pill ...
The DISCOVER trial that compared descovy versus truvada for PrEP showed that descovy produced safer kidney and bone outcomes. [40] The injectable form of PrEP, Cabotegravir, shares similar side effects to oral PrEP such as nausea and headache. However, one of the most common side effect is pain at injection site. [21]
Gilead also manufactures Truvada and Descovy, the two daily oral tablets approved for use as pre-exposure prophylaxis, or PrEP. The pharma giant has already secured approval for the injectable ...
Since 2021, Truvada has been available from multiple generic manufacturers and now often costs as little as $25 to $35 per month, although in some cases up to $600. ViiV lists Apretude at $1,878 ...
It is hoped that those unable to negotiate condom use with their sexual partners would be able to reduce their risk of HIV infection with the use of an oral (or injectable) prophylactic drug. Current PrEP candidates in development include tenofovir and Truvada (a combination of two ARV compounds, tenofovir and emtricitabine). [34]
Truvada: emtricitabine tenofovir disoproxil: August 2, 2004 Gilead Sciences: No Atripla: emtricitabine tenofovir disoproxil efavirenz: July 12, 2006 Gilead Sciences Bristol-Myers Squibb: Yes Complera (US) Eviplera (EU, RU) emtricitabine tenofovir disoproxil rilpivirine: August 10, 2011 Gilead Sciences Janssen Pharmaceutica: Yes Stribild ...
The U.S. Preventive Services Task Force found that the HIV pre-exposure prophylaxis drugs provide a “substantial net benefit” for those who are at higher risk of HIV.